Company / Cash & Equivalents
LIFECORE BIOMEDICAL, INC. \DE\ Cash & Equivalents History
FY2012-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$2.9M
FY2019
5-year range
$2.9M / $14.2M
FY2015-FY2019
Trend
-51.7%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $14M to $3M over the past 2 years.
Based on SEC 10-K filings.
$3M in FY2019 with a 5-year CAGR of -33.4%.
Declined from $14M to $3M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -41.2%
- 5-Year CAGR
- -33.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -33.4%, indicating a declining trend.
- In FY2019, cash & equivalents decreased 51.7% year-over-year.
- Peak cash & equivalents was recorded in FY2013.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $2.9M | -51.7% |
| FY2018 | $6.0M | -57.9% |
| FY2017 | $14.2M | +0.0% |
| FY2016 | $14.2M | +3.8% |
| FY2015 | $13.7M | -38.1% |
| FY2014 | $22.2M | -20.3% |
| FY2013 | $27.8M | +0.0% |
| FY2012 | $27.8M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026